Considerable surgeon-level variation in radical prostatectomy

Considerable surgeon-level variation in radical prostatectomy

(HealthDay)—Considerable practice variation exists among surgeons at a high-volume academic center when selecting patients with prostate cancer to undergo radical prostatectomy, according to a study published in the March issue of The Journal of Urology.

Hiten D. Patel, M.D., M.P.H., from Johns Hopkins Medical Institutions in Baltimore, and colleagues examined practice variability among urologists practicing at a high-volume academic center. The authors examined the percent of patients at low risk treated with in a given year and assessed the proportion of variance due to surgeon and temporal effects.

The researchers found that the percent of low-risk patients treated with prostatectomy increased 3.49 percent per year from 1991 to 2001 and decreased by 1.73 percent annually from 2001 to 2013. From 1991 to 2001, in a given year, greater surgeon experience correlated with a higher percent of patients at low risk treated with prostatectomy (0.46 percent per year of experience). High-volume surgeons operated on a greater percent of low-risk patients (3.54 percent). In a given year, surgeon level and temporal effects accounted for 24 and 70 percent, respectively, of the variance in the percent of at low risk treated with radical prostatectomy.

"In addition to patient decision support tools, publicly reporting individual practice patterns at the provider level could decrease the overtreatment of low-risk ," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)

Journal information: Journal of Urology

Copyright © 2015 HealthDay. All rights reserved.

Citation: Considerable surgeon-level variation in radical prostatectomy (2015, February 16) retrieved 6 May 2024 from https://medicalxpress.com/news/2015-02-considerable-surgeon-level-variation-radical-prostatectomy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

PDE-5 inhibitors tied to prostate cancer biochemical recurrence

4 shares

Feedback to editors